Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 182,500 Ordinary Shares on October 31, 2013.
- Price Range: Highest price paid was 1,653.50 pence; lowest price paid was 1,636.50 pence.
- Treasury Holdings (Settled): 507,894,912 shares (9.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,198,912 shares (10.45% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,862,396,552 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 182,500 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.45% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report to confirm the 9.46% ownership stake.
- Confirm the settlement status of the 182,500 shares purchased on October 31, 2013, to reconcile the difference between settled and unsettled Treasury holdings.
- Review the Financial Conduct Authority's Disclosure and Transparency Rules to understand the notification thresholds for shareholders based on the 4,862,396,552 shares in issue.